title: Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
abstract: Abstract Several molecular markers, such as NPM1, FLT3 and CEBPA, have been incorporated into both the World Health Organization and European LeukemiaNet classifications as routine assessments for the diagnosis and evaluation of prognostic significance in acute myeloid leukemia (AML). Lipocalin 2 (LCN2) is related to cancer development and is believed to be associated with the outcome of cytogenetically normal (CN)-AML. In the present study, we analyzed the prognostic effects and interactions of LCN2 expression (by molecular analysis, quantitative real-time polymerase chain reaction [qRT-PCR]) with neucleophosmin 1, fms-related tyrosine kinase 3 (FLT3) and CCAAT/enhancer-binding protein alpha mutations in 85 patients with CN-AML receiving intensive induction chemotherapy. Our results indicate that patients with higher LCN2 mRNA expression in the bone marrow (LCN2high), especially in combination with wild type FLT3-ITD, had better prognoses. FLT3-ITD compensated LCN2-overexpression-enhanced oxidative stress-induced apoptosis in cell line studies. In conclusion, LCN2high was associated with better prognosis, and FLT3 status had an adjuvant effect on overall survival.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
authors.forename: Wen-Chi
authors.initials: WC
authors.lastname: Yang
authors.forename: Pai-Mei
authors.initials: PM
authors.lastname: Lin
authors.forename: Ming-Yu
authors.initials: MY
authors.lastname: Yang
authors.forename: Yi-Chang
authors.initials: YC
authors.lastname: Liu
authors.forename: Chao-Sung
authors.initials: CS
authors.lastname: Chang
authors.forename: Wen-Chien
authors.initials: WC
authors.lastname: Chou
authors.forename: Jui-Feng
authors.initials: JF
authors.lastname: Hsu
authors.forename: Chiung-Tang
authors.initials: CT
authors.lastname: Huang
authors.forename: Shih-Feng
authors.initials: SF
authors.lastname: Cho
authors.forename: Wen-Hui
authors.initials: WH
authors.lastname: Yu
authors.forename: Sheng-Fung
authors.initials: SF
authors.lastname: Lin
mesh_terms: D000209:Acute-Phase Proteins / Q000235:genetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics; D016022:Case-Control Studies; D002460:Cell Line; D005260:Female; D015870:Gene Expression; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D059785:Karyotype; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D000071068:Lipocalin-2; D054834:Lipocalins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics; D000090243:Nucleophosmin; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D000209:Acute-Phase Proteins; D022762:CCAAT-Enhancer-Binding Proteins; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D000090243:Nucleophosmin; D051941:fms-Like Tyrosine Kinase 3